Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.77 | N/A | +7.91% |
management commentary, guidance changes, and full analysis available with Pro.
| +7.91% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our shareholders.
This earnings report indicates that Johnson & Johnson performed better than expected in terms of earnings per share. However, the lack of revenue data and guidance leaves some uncertainty about future performance. The stock reaction is not available, which may suggest limited immediate market response to the earnings announcement.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FB FINL CORP
Apr 14, 2025